Nguyen HQ et al. - Highly active antiretroviral therapy (HAART) and chemotherapy are important in clinical Kaposi sarcoma response. Methods
Aim was to 1) evaluate the role of HAART and chemotherapy on tumor response among AIDS-related Kaposi sarcoma pts and 2) identify factors associated with response
114 pts from two HIV clinics with a diagnosis of Kaposi sarcoma were enrolled
Records were reviewed to confirm diagnosis and abstract clinical and chemotherapy information
Demographics, laboratory values, and HAART use were abstracted electronically
Cox's proportional hazards models identified predictors of Kaposi sarcoma improvement and resolution
Results
64 pts with confirmed Kaposi sarcoma
In a 36 mos f/u of diagnosis, the rate of improvement was 77% and that of complete resolution was 51%
Recent chemotherapy was associated with Kaposi sarcoma improvement
Recent HIV viral load and HAART were associated with both improvement and resolution
No measured baseline characteristics or recent CD4 T-cell counts predicted improvement or resolution
Recent chemotherapy and HAART were predictors of improvement
Only recent HAART was associated with resolution
Response was not associated with type of HAART regimen
See all
